Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH phase 3 trial of zilebesiran added to standard therapy in adults with uncontrolled hypertension and established cardiovascular disease or high cardiovascular risk
CTR20261053Phase 3Active
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and cardiac morbidity comparing Zilebesiran added to standard therapy with Placebo added to standard therapy (2 arms). Primary endpoint: Time to first major adverse cardiovascular event or heart failure event. Started Jun 2026; status: active.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on CTR20261053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261053.